Ospamox (Amoxicillin Trihydrate)

Amoxicillin Trihydrate, the active ingredient in Ospamox, is a beta-lactam antibiotic presented as a unknown strength/unknown form for oral use. It treats bacterial infections in adults and children. GNH USA supplies Ospamox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ospamox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ospamox is a broad‑spectrum antibiotic that acts on bacterial cell wall synthesis pathways.

- Acute acute‑bacterial     :     ​                                                                                                ​ - Otitis media: Reduces bacterial load and alleviates symptoms in middle‑ear infections. - Community‑acquired pneumonia: Helps eradicate the causative organisms and improve respiratory function. - Uncomplicated urinary tract infection: Clears the infection and relieves dysuria. - Skin and soft‑tissue infections: Controls bacterial proliferation in cellulitis and wound infections. - Dental abscess: Eliminates infection and reduces pain associated with dental pulp involvement.

Amoxicillin is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects: - Diarrhea: mild to moderate loose stools. - Nausea: occasional upset stomach. - Rash: transient skin erythema. - Headache: mild headache. - Vaginal candidiasis: yeast overgrowth in some women. - Taste alteration: temporary metallic taste.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Stevens‑Stevens                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ...

The    ... ... ... ... ... ... ... ... ...